The Asia Pacific Opioid Use Disorder (OUD) Market would witness market growth of 10.9% CAGR during the forecast period (2023-2030).
One of the main drivers propelling the market is the rise in the number of drugs approved for treating opioid use disorder, the rise in opioid addiction cases in developed nations, and the growing acceptance of buprenorphine patches as a viable treatment option. Every year, there are an increasing number of cases of opioid addiction, making opioid dependency a severe public health concern. In order to reduce the perception of pain, opioids interact with opioid receptors in the body and the brain. Opioids can be either natural, semi-natural, or synthetic chemicals.
According to the Indian government, the country's opioid consumption problems (harmful use and dependency) is predicted to affect 2.06% of Indians overall and 0.55% of Indians individually. Heroin dependence is greater than that of opium and pharmaceutical opioid dependence. Only several states—Uttar Pradesh, Punjab, Haryana, Delhi, Maharashtra, Rajasthan, Andhra Pradesh, and Gujarat—contribute more than half of the estimated 60 lakh people with opioid use disorders (harmful or dependent pattern) in the nation. There are approximately 40,00,000 opioid users overall in India between the ages of 10 and 17 and 1,86,440,000 between the ages of 18 and 75.
China has serious drug misuse concerns that seem to be getting worse over time. Because of its severe medical effects, impact on risk for HIV/AIDS and criminal behavior, poor rates of recovery, and high rates of relapse, opiate use seriously threatens China's public health and social security. MMT and other cutting-edge treatments for opiate addiction are essential to be adopted in the nation. Thus, the market for opioid use disorders is expanding due to the rising prevalence of opioid drugs and addiction.
The China market dominated the Asia Pacific Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $422.7 million by 2030. The Japan market is poised to grow at a CAGR of 10.1% during (2023 - 2030). Additionally, The India market would display a CAGR of 11.4% during (2023 - 2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Opioid Use Disorder (OUD) Market is Projected to reach USD 6.4 Billion by 2030, at a CAGR of 9.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 Asia Pacific Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 Asia Pacific Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 Asia Pacific Opioid Use Disorder (OUD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
4.1 Asia Pacific Buprenorphine Market by Country
4.2 Asia Pacific Methadone Market by Country
4.3 Asia Pacific Naltrexone Market by Country
Chapter 5. Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
5.1 Asia Pacific Parenteral Market by Country
5.2 Asia Pacific Oral Market by Country
Chapter 6. Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 Asia Pacific Hospital Pharmacies Market by Country
6.2 Asia Pacific Retail Pharmacies & Stores Market by Country
6.3 Asia Pacific Online Pharmacies Market by Country
Chapter 7. Asia Pacific Opioid Use Disorder (OUD) Market by Country
7.1 China Opioid Use Disorder (OUD) Market
7.1.1 China Opioid Use Disorder (OUD) Market by Drug Class
7.1.2 China Opioid Use Disorder (OUD) Market by Route of Administration
7.1.3 China Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 Japan Opioid Use Disorder (OUD) Market
7.2.1 Japan Opioid Use Disorder (OUD) Market by Drug Class
7.2.2 Japan Opioid Use Disorder (OUD) Market by Route of Administration
7.2.3 Japan Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 India Opioid Use Disorder (OUD) Market
7.3.1 India Opioid Use Disorder (OUD) Market by Drug Class
7.3.2 India Opioid Use Disorder (OUD) Market by Route of Administration
7.3.3 India Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 South Korea Opioid Use Disorder (OUD) Market
7.4.1 South Korea Opioid Use Disorder (OUD) Market by Drug Class
7.4.2 South Korea Opioid Use Disorder (OUD) Market by Route of Administration
7.4.3 South Korea Opioid Use Disorder (OUD) Market by Distribution Channel
7.5 Singapore Opioid Use Disorder (OUD) Market
7.5.1 Singapore Opioid Use Disorder (OUD) Market by Drug Class
7.5.2 Singapore Opioid Use Disorder (OUD) Market by Route of Administration
7.5.3 Singapore Opioid Use Disorder (OUD) Market by Distribution Channel
7.6 Malaysia Opioid Use Disorder (OUD) Market
7.6.1 Malaysia Opioid Use Disorder (OUD) Market by Drug Class
7.6.2 Malaysia Opioid Use Disorder (OUD) Market by Route of Administration
7.6.3 Malaysia Opioid Use Disorder (OUD) Market by Distribution Channel
7.7 Rest of Asia Pacific Opioid Use Disorder (OUD) Market
7.7.1 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
7.7.2 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
7.7.3 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
TABLE 1 Asia Pacific Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 3 Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 4 Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 5 Asia Pacific Buprenorphine Market by Country, 2019 - 2022, USD Million
TABLE 6 Asia Pacific Buprenorphine Market by Country, 2023 - 2030, USD Million
TABLE 7 Asia Pacific Methadone Market by Country, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Methadone Market by Country, 2023 - 2030, USD Million
TABLE 9 Asia Pacific Naltrexone Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Naltrexone Market by Country, 2023 - 2030, USD Million
TABLE 11 Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 13 Asia Pacific Parenteral Market by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Parenteral Market by Country, 2023 - 2030, USD Million
TABLE 15 Asia Pacific Oral Market by Country, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Oral Market by Country, 2023 - 2030, USD Million
TABLE 17 Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 21 Asia Pacific Retail Pharmacies & Stores Market by Country, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Retail Pharmacies & Stores Market by Country, 2023 - 2030, USD Million
TABLE 23 Asia Pacific Online Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Online Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 25 Asia Pacific Opioid Use Disorder (OUD) Market by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific Opioid Use Disorder (OUD) Market by Country, 2023 - 2030, USD Million
TABLE 27 China Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 28 China Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 29 China Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 30 China Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 31 China Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 32 China Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 33 China Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 China Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 Japan Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 36 Japan Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 37 Japan Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 38 Japan Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 39 Japan Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 40 Japan Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 41 Japan Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Japan Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 India Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 44 India Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 45 India Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 46 India Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 47 India Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 48 India Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 49 India Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 India Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 South Korea Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 52 South Korea Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 53 South Korea Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 54 South Korea Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 55 South Korea Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 56 South Korea Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 57 South Korea Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 South Korea Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Singapore Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 60 Singapore Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 61 Singapore Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 62 Singapore Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 63 Singapore Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 64 Singapore Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 65 Singapore Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Singapore Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Malaysia Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 68 Malaysia Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 69 Malaysia Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 70 Malaysia Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 71 Malaysia Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 72 Malaysia Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 73 Malaysia Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Malaysia Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of Asia Pacific Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 76 Rest of Asia Pacific Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 77 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 78 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 79 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 80 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 81 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information – Indivior PLC (Reckitt Benckiser Group plc)
TABLE 84 Key Information – collegium pharmaceutical
TABLE 85 Key Information – Orexo AB
TABLE 86 Key Information – Alkermes PLC
TABLE 87 Key Information – Titan Pharmaceuticals, Inc.
TABLE 88 Key Information – Camurus AB
TABLE 89 KEY INFORMATION – AstraZeneca PLC
TABLE 90 Key Information – Hikma Pharmaceuticals PLC
TABLE 91 Key information – Mallinckrodt PLC
TABLE 92 key information – Viatris, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Opioid Use Disorder (OUD) Market share by Drug Class, 2022
FIG 3 Asia Pacific Opioid Use Disorder (OUD) Market share by Drug Class, 2030
FIG 4 Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2030, USD Million
FIG 5 Asia Pacific Opioid Use Disorder (OUD) Market share by Route of Administration, 2022
FIG 6 Asia Pacific Opioid Use Disorder (OUD) Market share by Route of Administration, 2030
FIG 7 Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2030, USD Million
FIG 8 Asia Pacific Opioid Use Disorder (OUD) Market share by Distribution Channel, 2022
FIG 9 Asia Pacific Opioid Use Disorder (OUD) Market share by Distribution Channel, 2030
FIG 10 Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 Asia Pacific Opioid Use Disorder (OUD) Market share by Country, 2022
FIG 12 Asia Pacific Opioid Use Disorder (OUD) Market share by Country, 2030
FIG 13 Asia Pacific Opioid Use Disorder (OUD) Market by Country, 2019 - 2030, USD Million